LOS ANGELES--(BUSINESS WIRE)--Feb. 2, 2006--Cougar Biotechnology, Inc., a privately held biotechnology company, today announced that its Investigational New Drug (IND) application for the Company's drug CB7630 (abiraterone acetate) has been approved by the U.S. Food and Drug Administration (FDA). This will allow Cougar to conduct a Phase I clinical trial of CB7630, an orally active inhibitor of the steroidal enzyme 17alpha-hydroxylase/C17,20 lyase, for the treatment of advanced prostate cancer in the United States.
